The emerging threat of artemisinin resistance in malaria: focus on artemether-lumefantrine

References

• World Health Organization (WHO) World Malaria Report 2013. Available from: www.who.int/malaria/publications/world_malaria_report_2013/report/en/ [Last accessed 30 April 2015]
   Google Scholar
• World Health Organization (WHO) Guidelines for the Treatment of Malaria. Third Edition. WHO, 2015. Available from: www.who.int/malaria/publications/atoz/9789241549127/en/ [Last accessed 30 April 2015]
   Google Scholar
• Noedl H, Se Y, Sriwichai S, et al. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis 2010;51:e82-9
   PubMed Web of Science ®Google Scholar
• Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009;361:455-67
   PubMed Web of Science ®Google Scholar
• Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012;379:1960-6
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO) Global Report on Antimalarial Efficacy and Drug Resistance: 2000–2010. November 2010. Available at www.who.int/malaria/publications/atoz/9789241500470/en/ [Last accessed 30 April 2015]
   Google Scholar
• Ogutu B. Artemether and lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Expert Opin Pharmacother 2013;14:643-54
   PubMed Web of Science ®Google Scholar
• Makanga M, Bassat Q, Falade CO, et al. Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. Am J Trop Med Hyg 2011;85:793-804
   PubMed Web of Science ®Google Scholar
• White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 1999;37:105-25
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO) Global Plan for Artemisinin Resistance Containment (GPARC), January 2011. Available from: www.who.int/malaria/publications/atoz/9789241500838/en/ [Last accessed 30 April 2015]
   Google Scholar
• Seboxa T, Mao P, Pinchouk N, et al. Artemether-lumefantrin (Coartem) and artesunate with sulfadoxine-pyrimethamine therapeutic efficacy in the treatment of uncomplicated malaria at Gilgel Gibe II (GGII) South-Western Ethiopia. Ethiop Med J 2010;48:285-91
   PubMedGoogle Scholar
• Eshetu T, Abdo N, Bedru KH, et al. Open-label trial with artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria three years after its broad introduction in Jimma Zone. Ethiopia. Malar J 2012;11:240
   PubMedGoogle Scholar
• Kinfu G, Gebre-Selassie S, Fikrie N. Therapeutic efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Northern Ethiopia. Malar Res Treat 2012; 548710
   PubMedGoogle Scholar
• Hwang J, Alemayehu BH, Hoos D, et al. In vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in Central Ethiopia. Malar J 2011;10:209
   PubMedGoogle Scholar
• Borrmann S, Sasi P, Mwai L, et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One 2011;6:e26005
   PubMed Web of Science ®Google Scholar
• Sawa P, Shekalaghe SA, Drakeley CJ, et al. Malaria transmission after artemether lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. J Infect Dis 2013;207:1637-2645
   PubMed Web of Science ®Google Scholar
• Beshir KB, Sutherland CJ, Sawa P, et al. Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence. J Infect Dis 2013;208:2017-24
   PubMed Web of Science ®Google Scholar
• Ogutu BR, Onyango KO, Koskei N, et al. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study. Malar J 2014;13:33
   PubMedGoogle Scholar
• Agarwal A, McMorrow M, Onyango P, et al. A randomized trial of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated malaria among children in Western Kenya. Malar J 2013;12:254
   PubMedGoogle Scholar
• Elamin SB, Awad AI, Eltayeb IB, et al. Descriptive study on the efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Sudan. Eur J Clin Pharmacol 2010;66:231-7
   PubMed Web of Science ®Google Scholar
• Adam I, Salah MT, Eltahir HG, et al. Dihydroartemisinin-piperaquine versus artemether lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in Central Sudan. Ann Trop Med Parasitol 2010;104:319-26
   PubMed Web of Science ®Google Scholar
• Gadalla NB, Adam I, Elzaki S-E, et al. Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine. Antimicrob Agents Chemother 2011;55:5408-11
   PubMed Web of Science ®Google Scholar
• Carlsson AM, Ngasala BE, Dahlström S, et al. Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria. Malar J 2011;10:380
   PubMedGoogle Scholar
• Ngasala BE, Malmberg M, Carlsson AM, et al. Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. Clin Infect Dis 2011;52:873-82
   PubMed Web of Science ®Google Scholar
• Ngasala BE, Malmberg M, Carlsson AM, et al. Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study. Malar J 2011;10:64
   PubMedGoogle Scholar
• Kamugisha E, Jing S, Minde M, et al. Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, North-Western Tanzania. Malar J 2012;11:58
   PubMedGoogle Scholar
• Joseph D, Kabanywanyi AM, Hulser R, et al. Exploration of in vivo efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria in under fives in Tabora Region, Tanzania. Malar J 2013;12:60
   PubMedGoogle Scholar
• Maganda BA, Minzi OM, Kamuhabwa AA, et al. Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy. Malar J 2014;13:205
   PubMed Web of Science ®Google Scholar
• Minzi O, Maige S, Sasi P, Ngasala B. Adherence to artemether-lumefantrine drug combination: a rural community experience six years after change of malaria treatment policy in Tanzania. Malar J 2014;13:267
   PubMedGoogle Scholar
• Shayo A, Mandara CI, Shahada F, et al. Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern Tanzania. Malar J 2014;13:376
   PubMedGoogle Scholar
• Clark TD, Njama-Meya D, Nzarubara B, et al. Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children. PLoS One 2010;5:e11759
   PubMedGoogle Scholar
• Piola P, Nabasumba C, Turyakira E, et al. Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Lancet Infect Dis 2010;10:762-9
   PubMed Web of Science ®Google Scholar
• Arinaitwe E, Sandison TG, Wanzira H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis 2009;49:1629-37
   PubMed Web of Science ®Google Scholar
• Verret WJ, Arinaitwe E, Wanzira H, et al. Effect of nutritional status on response to treatment with artemisinin-based combination therapy in young Ugandan children with malaria. Antimicrob Agents Chemother 2011;55:2629-35
   PubMed Web of Science ®Google Scholar
• Yeka A, Tibenderana J, Achan J, et al. Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children. PLoS One 2013;8:e53772
   PubMedGoogle Scholar
• Muhindo MK, Kakuru A, Jagannathan P, et al. Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria. Malar J 2014;13:32
   PubMed Web of Science ®Google Scholar
• Eziefula AC, Bousema T, Yeung S, et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. Lancet Infect Dis 2014;14:130-9
   PubMed Web of Science ®Google Scholar
• Kakuru A, Achan J, Muhindo MK, et al. Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. Clin Infect Dis 2014;59:446-53
   PubMed Web of Science ®Google Scholar
• Kinde-Gazard D, Ogouyèmi-Hounto A, Capo-Chichi L, et al. A randomized clinical trial comparing the effectiveness and tolerability of artemisinine-naphthoquine (Arco®) and artemether-lumefantrine (Coartem®) in the treatment of uncomplicated malaria in Benin. Bull Soc Pathol Exot 2012;105:208-14
   PubMedGoogle Scholar
• Siribié M, Diarra A, Tiono AB, et al. Efficacy of artemether-lumefantrine in the treatment of uncomplicated malaria in children living in a rural area of Burkina Faso in 2009. Bull Soc Pathol Exot 2012;105:202-7
   PubMedGoogle Scholar
• Tinto H, Diallo S, Zongo I, et al. Effectiveness of artesunate-amodiaquine vs. artemether lumefantrine for the treatment of uncomplicated falciparum malaria in Nanoro, Burkina Faso: a non-inferiority randomised trial. Trop Med Int Health 2014;19:469-75
   PubMed Web of Science ®Google Scholar
• Toure OA, Kouame MG, Didier YJ, et al. Artesunate/mefloquine paediatric formulation vs. artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum in Anonkoua Kouté, Côte d’Ivoire. Trop Med Int Health 2011;16:290-7
   PubMed Web of Science ®Google Scholar
• Abuaku B, Duah N, Quaye L, et al. Therapeutic efficacy of artemether-lumefantrine combination in the treatment of uncomplicated malaria among children under five years of age in three ecological zones in Ghana. Malar J 2012;11:388
   PubMedGoogle Scholar
• Ursing J, Kofoed P-E, Rodrigues A, et al. Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial. J Infect Dis 2011;203:109-16
   PubMed Web of Science ®Google Scholar
• Schramm B, Valeh P, Baudin E, et al. Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial. Malar J 2013;12:251
   PubMedGoogle Scholar
• Rasheed A, Khan SM, Awan MY, et al. Efficacy and safety of artemether-lumefantrine in uncomplicated falciparum malaria in Liberia. J Pak Med Assoc 2011;61:131-4
   PubMed Web of Science ®Google Scholar
• Sagara I, Fofana B, Gaudart J, et al. Repeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impact. Am J Trop Med Hyg 2012;87:50-6
   PubMed Web of Science ®Google Scholar
• Gbotosho GO, Sowunmi A, Happi CT, Okuboyejo TM. Therapeutic efficacies of artemisinin-based combination therapies in Nigerian children with uncomplicated falciparum malaria during five years of adoption as first-line treatments. Am J Trop Med Hyg 2011;84:936-43
   PubMed Web of Science ®Google Scholar
• Okafor HU, Shu EN, Oguonu T. Therapeutic efficacy and effect on gametocyte carriage of an artemisinin and a non-based combination treatment in children with uncomplicated P. falciparum malaria, living in an area with high-level chloroquine resistance. J Trop Pediatr 2010;56:398-406
   PubMed Web of Science ®Google Scholar
• Opara K, Udoidung N, Okokon J, et al. Efficacy of arthemether–lumenfantrine against uncomplicated Plasmodium falciparum malaria in infants and children in Uyo, Nigeria. Internet J Infect Dis 2010;8:1
   Google Scholar
• Falade CO, Dada-Adegbola HO, Ogunkunle OO, et al. Evaluation of the comparative efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine and artesunate-amodiaquine-chlorpheniramine (ArtemocloTM) for the treatment of acute uncomplicated malaria in Nigerian children. Med Princ Pract 2014;23:204-11
   PubMed Web of Science ®Google Scholar
• Gbotosho GO, Sowunmi A, Okuboyejo TM, Happi CT. Oral artesunate-amodiaquine and artemether-lumefantrine in the treatment of uncomplicated hyperparasitaemic Plasmodium falciparum malaria in children. J Trop Pediatr 2012;58:151-3
   PubMed Web of Science ®Google Scholar
• Gbotosho GO, Sowunmi A, Okuboyejo TM, et al. A simple dose regimen of artesunate and amodiaquine based on age or body weight range for uncomplicated falciparum malaria in children: comparison of therapeutic efficacy with standard dose regimen of artesunate and amodiaquine and artemether-lumefantrine. Am J Ther 2012;19:e122-31
   PubMedGoogle Scholar
• Gbotosho GO, Sowunmi A, Okuboyejo TM, et al. Therapeutic efficacy and effects of artemether-lumefantrine and artesunate-amodiaquine coformulated or copackaged on malaria-associated anemia in children with uncomplicated Plasmodium falciparum malaria in Southwest Nigeria. Am J Trop Med Hyg 2011;84:813-19
   PubMed Web of Science ®Google Scholar
• Ojurongbe O, Lawal OA, Abiodun OO, et al. Efficacy of artemisinin combination therapy for the treatment of uncomplicated falciparum malaria in Nigerian children. J Infect Dev Ctries 2013;7:975-82
   PubMedGoogle Scholar
• Okonta MJ, Nduka SO, Ilodigwe EE, Anetoh MU. Comparative assessment of two artemisinin based combination therapies in the treatment of uncomplicated malaria among university students in Nigeria. Int J Drug Dev Res 2013;5:211-21
   Google Scholar
• Michael OS, Gbotosho GO, Folarin OA, et al. Early variations in Plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin based combinations: implications on delayed parasite clearance. Malar J 2010;9:335
   PubMedGoogle Scholar
• Oguche S, Okafor HU, Watila I, et al. Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five-year-old Nigerian children. Am J Trop Med Hyg 2014;91:925-35
   PubMed Web of Science ®Google Scholar
• Ndiaye JL, Faye B, Gueye A, et al. Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial. Malar J 2011;10:237
   PubMedGoogle Scholar
• Faye B, Ndiaye JL, Tine R, et al. A randomized trial of artesunate mefloquine versus artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Senegalese children. Am J Trop Med Hyg 2010;82:140-4
   PubMed Web of Science ®Google Scholar
• Tine RCK, Faye B, Sylla K, et al. Efficacy and tolerability of a new formulation of artesunate-mefloquine for the treatment of uncomplicated malaria in adult in Senegal: open randomized trial. Malar J 2012;11:416
   PubMed Web of Science ®Google Scholar
• Sylla K, Abiola A, Tine RCK, et al. Monitoring the efficacy and safety of three artemisinin-based combination therapies in Senegal: results from two years surveillance. BMC Infect Dis 2013;13:598
   PubMedGoogle Scholar
• Faye B, Offianan AT, Ndiaye JL, et al. Efficacy and tolerability of artesunate amodiaquine (Camoquin plus) versus artemether-lumefantrine (Coartem) against uncomplicated Plasmodium falciparum malaria: multisite trial in Senegal and Ivory Coast. Trop Med Int Health 2010;15:608-13
   PubMed Web of Science ®Google Scholar
• Dunyo S, Sirugo G, Sesay S, et al. Randomized trial of safety and effectiveness of chlorproguanil-dapsone and lumefantrine-artemether for uncomplicated malaria in children in the Gambia. PLoS One 2011;6:e17371
   PubMedGoogle Scholar
• Dorkenoo MA, Barrette A, Agbo YM, et al. Surveillance of the efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum among children under five in Togo, 2005-2009. Malar J 2012;11:338
   PubMed Web of Science ®Google Scholar
• Whegang SY, Tahar R, Foumane VN, et al. Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon. Malar J 2010;9:56
   PubMedGoogle Scholar
• Ali IM, Netongo PM, Atogho-Tiedeu B, et al. Amodiaquine-artesunate versus artemether-lumefantrine against uncomplicated malaria in children less than 14 years in Ngaoundere, North Cameroon: efficacy, safety, and baseline drug resistant mutations in pfcrt, pfmdr1, and pfdhfr genes. Malar Res Treat 2013;234683
   PubMedGoogle Scholar
• Djallé D, Njuimo SP, Manirakiza A, et al. Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial. Malar J 2014;13:9
   PubMed Web of Science ®Google Scholar
• Nambei WS, Yaya EL, Pounguinza S, et al. Efficacy and safety of antimalarial combinations for treatment of uncomplicated malaria in children in Bangui, Central African Republic. Méd Santé Trop 2013;23:313-19
   PubMedGoogle Scholar
• Ndounga M, Tahar R, Casimiro PN, et al. Clinical efficacy of artemether-lumefantrine in Congolese children with acute uncomplicated falciparum malaria in Brazzaville. Malar Res Treat 2012; 749479
   PubMedGoogle Scholar
• Espié E, Lima A, Atua B, et al. Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial. Malar J 2012;11:174
   PubMedGoogle Scholar
• Onyamboko MA, Fanello CI, Wongsaen K, Tarning J. Randomized comparison of the efficacies and tolerabilities of three artemisinin-based combination treatments for children with acute Plasmodium falciparum malaria in the Democratic Republic of the Congo. Antimicrob Agents Chemother 2014;58:5528-36
   PubMed Web of Science ®Google Scholar
• Yavo W, Faye B, Kuete T, et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Malar J 2011;10:198
   PubMed Web of Science ®Google Scholar
• Menan H, Faye O, Same-Ekobo A, et al. Comparative study of the efficacy and tolerability of dihydroartemisinin-piperaquine-trimethoprim versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal. Malar J 2011;10:185
   PubMedGoogle Scholar
• Faye B, Kuété T, Kiki-Barro CP, et al. Multicentre study evaluating the non-inferiority of the new paediatric formulation of artesunate/amodiaquine versus artemether/lumefantrine for the management of uncomplicated Plasmodium falciparum malaria in children in Cameroon, Ivory Coast and Senegal. Malar J 2012;11:433
   PubMedGoogle Scholar
• Abram S, Harrison WJ, Cashman J, et al. The effects of introducing artemether-lumefantrine malaria treatment and insecticide-impregnated bed nets to an elective surgical hospital. Trop Doct 2011;41:15-17
   PubMed Web of Science ®Google Scholar
• Nhama A, Bassat Q, Enosse S, et al. In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique. Malar J 2014;13:309
   PubMedGoogle Scholar
• Vaughan-Williams CH, Raman J, Raswiswi E, et al. Assessment of the therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Northern KwaZulu-Natal: an observational cohort study. Malar J 2012;11:434
   PubMedGoogle Scholar
• Nambozi M, Van Geertruyden J-P, Hachizovu S, et al. Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar J 2011;10:50
   PubMedGoogle Scholar
• Four Artemisinin-Based Combinations (4ABC) Study Group. A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med 2011;8:e1001119
   PubMedGoogle Scholar
• Bassat Q, Mulenga M, Tinto H, et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One 2009;4:e7871
   PubMed Web of Science ®Google Scholar
• Tshefu AK, Gaye O, Kayentao K, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non inferiority trial. Lancet 2010;375:1457-67
   PubMed Web of Science ®Google Scholar
• Kayentao K, Doumbo OK, Pénali LK, et al. Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Malar J 2012;11:364
   PubMedGoogle Scholar
• Duparc S, Borghini-Fuhrer I, Craft CJ, et al. Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials. Malar J 2013;12:70
   PubMedGoogle Scholar
• Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2014;371:411-23
   PubMed Web of Science ®Google Scholar
• Thriemer K, Starzengruber P, Khan WA, et al. Azithromycin combination therapy for the treatment of uncomplicated falciparum malaria in Bangladesh: an open-label randomized, controlled clinical trial. J Infect Dis 2010;202:392-8
   PubMed Web of Science ®Google Scholar
• Singh H, Kumar BN, Dulhani N, Tiwari P. A comparative study of artesunatelumefantrine vs. chloroquine-pyrimethamine-sulfadoxine efficacy for the treatment of uncomplicated Plasmodium falciparum in tribal population in Bastar (Chhattisgarh). Internet J Pharmacol 2010;8:1
   Google Scholar
• Valecha N, Mohanty S, Srivastava P, et al. Efficacy of artemether-lumefantrine in area of high malaria endemicity in India and its correlation with blood concentration of lumefantrine. Am J Trop Med Hyg 2012;86:395-7
   PubMed Web of Science ®Google Scholar
• Saha P, Guha SK, Das S, et al. Comparative efficacies of artemisinin combination therapies in Plasmodium falciparum malaria and polymorphism of pfATPase6, pfcrt, pfdhfr, and pfdhps genes in tea gardens of Jalpaiguri District, India. Antimicrob Agents Chemother 2012;56:2511-17
   PubMed Web of Science ®Google Scholar
• Pareek A, Chandurkar N, Srivastav V, et al. Comparative evaluation of efficacy and safety of artesunate-lumefantrine vs. artemether-lumefantrine fixed-dose combination in the treatment of uncomplicated Plasmodium falciparum malaria. Trop Med Int Health 2013;18:578-87
   PubMed Web of Science ®Google Scholar
• Valecha N, Krudsood S, Tangpukdee N, et al. Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated Plasmodium falciparum malaria: a comparative, multicenter, randomized clinical trial. Clin Infect Dis 2012;55:663-71
   PubMed Web of Science ®Google Scholar
• Song J, Socheat D, Tan B, et al. Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area. Malar J 2011;10:231
   PubMed Web of Science ®Google Scholar
• Sutanto I, Suprianto S, Widiaty A, et al. Good efficacy of artemether-lumefantrine for uncomplicated falciparum malaria in Eastern Sumba, East Nusatenggara. Indonesia. Acta Med Indones 2012;44:187-92
   PubMedGoogle Scholar
• Mayxay M, Khanthavong M, Chanthongthip O, et al. Efficacy of artemether-lumefantrine, the nationally-recommended artemisinin combination for the treatment of uncomplicated falciparum malaria, in Southern Laos. Malar J 2012;11:184
   PubMedGoogle Scholar
• Smithuis F, Kyaw MK, Phe O, et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis 2010;10:673-81
   PubMed Web of Science ®Google Scholar
• Nyunt MH, Kyaw MP, Win KK, et al. Field evaluation of HRP2 and pan pLDH-based immunochromatographic assay in therapeutic monitoring of uncomplicated falciparum malaria in Myanmar. Malar J 2013;12:123
   PubMedGoogle Scholar
• Senn N, Rarau P, Manong D, et al. Effectiveness of artemether/lumefantrine for the treatment of uncomplicated Plasmodium vivax and P. falciparum malaria in young children in Papua New Guinea. Clin Infect Dis 2013;56:1413-20
   PubMed Web of Science ®Google Scholar
• McCarthy JS, Sekuloski S, Griffin PM, et al. A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLoS One 2011;6:e21914
   PubMed Web of Science ®Google Scholar
• De la Hoz Restrepo F, Porras Ramírez A, Rico Mendoza A, et al. Artesunate + amodiaquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in the Colombian Pacific Region: a noninferiority trial. Rev Soc Bras Med Trop 2012;45:732-8
   PubMed Web of Science ®Google Scholar
• Vreden SGS, Jitan JK, Bansie RD, Adhin MR. Evidence of an increased incidence of day 3 parasitaemia in Suriname: an indicator of the emerging resistance of Plasmodium falciparum to artemether. Mem Instit Oswaldo Cruz 2013;108:968-73
   PubMed Web of Science ®Google Scholar
• Bouchaud O, Mühlberger N, Parola P, et al. Therapy of uncomplicated falciparum malaria in Europe: MALTHER – a prospective observational multicentre study. Malar J 2012;11:212
   PubMed Web of Science ®Google Scholar
• Das D, Price RN, Bethell D, et al. Early parasitological response following artemisinin-containing regimens: a critical review of the literature. Malar J 2013;12:125
   PubMed Web of Science ®Google Scholar
• Lemma H, Byass P, Desta A, et al. Deploying artemether-lumefantrine with rapid testing in Ethiopian communities: impact on malaria morbidity, mortality and healthcare resources. Trop Med Int Health 2010;15:241-50
   PubMed Web of Science ®Google Scholar
• Barnes KI, Chanda P, Ab Barnabas G. Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia. Malar J 2009;8(Suppl 1):S8
   PubMed Web of Science ®Google Scholar
• Sowunmi A, Adewoye EO, Gbotsho GO, et al. Factors contributing to delay in parasite clearance in uncomplicated falciparum malaria in children. Malar J 2010;9:53
   PubMedGoogle Scholar
• Smith A, Denholm J, Shortt J, Spelman D. Plasmodium species co-infection as a cause of treatment failure. Travel Med Infect Dis 2011;9:306-9
   PubMedGoogle Scholar
• Färnert A, Ursing J, Tolfvenstam T, et al. Artemether-lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveller with Plasmodium falciparum malaria after returning from Tanzania. Malar J 2012;11:176
   PubMedGoogle Scholar
• Dahlström S, Aubouy A, Maïga-Ascofaré O, et al. Plasmodium falciparum polymorphisms associated with ex vivo drug susceptibility and clinical effectiveness of artemisinin-based combination therapies in Benin. Antimicrob Agents Chemother 2014;58:1-10
   PubMed Web of Science ®Google Scholar
• Somé AF, Séré YY, Dokomajilar C, et al. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother 2010;54:1949-54
   PubMed Web of Science ®Google Scholar
• Menard S, Morlais I, Tahar R, et al. Molecular monitoring of Plasmodium falciparum drug susceptibility at the time of the introduction of artemisinin-based combination therapy in Yaoundé, Cameroon: implications for the future. Malar J 2012;11:113
   PubMedGoogle Scholar
• Mvumbi DM, Boreux R, Sacheli R. Assessment of pfcrt 72-76 haplotypes eight years after chloroquine withdrawal in Kinshasa, Democratic Republic of Congo. Malar J 2013;12:459
   PubMedGoogle Scholar
• Golassa L, Enweji N, Erko B, et al. High prevalence of pfcrt-CVIET haplotype in isolates from asymptomatic and symptomatic patients in South-Central Oromia. Ethiopia. Malar J 2014;13:120
   PubMedGoogle Scholar
• Lekana-Douki JB, Dinzouna Boutamba SD, Zatra R, et al. Increased prevalence of the Plasmodium falciparum Pfmdr1 86N genotype among field Isolates from Franceville, Gabon after replacement of chloroquine by artemether-lumefantrine and artesunate-mefloquine. Infect Genet Evol 2011;11:512-17
   PubMed Web of Science ®Google Scholar
• Zatra R, Lekana-douki JB, Lekoulou F, et al. In vitro antimalarial susceptibility and molecular markers of drug resistance in Franceville, Gabon. BMC Infect Dis 2012;12:307
   PubMedGoogle Scholar
• Duah NO, Matrevi SA, de Souza DK, et al. Increased pfmdr1 gene copy number and the decline in pfcrt and pfmdr1 resistance alleles in Ghanaian Plasmodium falciparum isolates after the change of anti-malarial drug treatment policy. Malar J 2013;12:377
   PubMed Web of Science ®Google Scholar
• Mwai L, Kiara SM, Abdirahman A, et al. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother 2009;53:5069-73
   PubMed Web of Science ®Google Scholar
• Vardo-Zalik AM, Zhou G, et al. Alterations in Plasmodium falciparum genetic structure two years after increased malaria control efforts in Western Kenya. Am J Trop Med Hyg 2013;88:29-36
   PubMed Web of Science ®Google Scholar
• Eyase FL, Akala HM, Ingasia L, et al. The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. Falciparum samples during 2008–2011. PLoS One 2013;8: e64299
   PubMed Web of Science ®Google Scholar
• Nkhoma S, Nair S, Mukaka M, et al. Parasites bearing a single copy of the multi-drug resistance gene (pfmdr-1) with wild-type SNPs predominate amongst Plasmodium falciparum isolates from Malawi. Acta Trop 2009;111:78-81
   PubMed Web of Science ®Google Scholar
• Raman J, Mauff K, Muianga P, et al. Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out. PLoS One 2011;6:e25992
   PubMedGoogle Scholar
• Thomsen TT, Madsen LB, Hansson HH, et al. Rapid selection of Plasmodium falciparum chloroquine resistance transporter gene and multidrug resistance gene-1 haplotypes associated with past chloroquine and present artemether-lumefantrine use in Inhambane District, southern Mozambique. Am J Trop Med Hyg 2013;88:536-41
   PubMed Web of Science ®Google Scholar
• Lobo E, de Sousa B, Rosa S, et al. Prevalence of pfmdr1 alleles associated with artemether-lumefantrine tolerance/resistance in Maputo before and after the implementation of artemisinin-based combination therapy. Malar J 2014;13:300
   PubMed Web of Science ®Google Scholar
• Issaka M, Salissou A, Arzika I, et al. Ex vivo responses of Plasmodium falciparum clinical isolates to conventional and new antimalarial drugs in Niger. Antimicrob Agents Chemother 2013;57:3415-19
   PubMed Web of Science ®Google Scholar
• Bustamante C, Folarin OA, Gbotosho GO, et al. In vitro-reduced susceptibility to artemether in P. falciparum and its association with polymorphisms on transporter genes. J Infect Dis 2012;206:324-32
   PubMed Web of Science ®Google Scholar
• Happi CT, Gbotosho GO, Folarin OA, et al. Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob Agents Chemother 2009;53:888-95
   PubMed Web of Science ®Google Scholar
• Zeile I, Gahutu JB, Shyirambere C, et al. Molecular markers of Plasmodium falciparum drug resistance in southern highland Rwanda. Acta Trop 2012;121:50-4
   PubMed Web of Science ®Google Scholar
• Fall B, Diawara S, Sow K, et al. Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs. Malar J 2011;10:310
   PubMedGoogle Scholar
• Wurtz N, Fall B, Pascual A, et al. Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal. Malar J 2012;11:197
   PubMed Web of Science ®Google Scholar
• Van Tyne D, Dieye B, Valim C, et al. Changes in drug sensitivity and anti-malarial drug resistance mutations over time among Plasmodium falciparum parasites in Senegal. Malar J 2013;12:441
   PubMedGoogle Scholar
• Fall B, Pascual A, Sarr FD, et al. Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study. Malar J 2013;12:107
   PubMedGoogle Scholar
• Wurtz N, Fall B, Pascual A, et al. Role of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine and dihydroartemisinin. Antimicrob Agents Chemother 2014;58:7032-40
   PubMed Web of Science ®Google Scholar
• Thomsen TT, Ishengoma DS, Mmbando BP, et al. Prevalence of single nucleotide polymorphisms in the Plasmodium falciparum multidrug resistance gene (Pfmdr-1) in Korogwe District in Tanzania before and after introduction of artemisinin-based combination therapy. Am J Trop Med Hyg 2011;85:979-83
   PubMed Web of Science ®Google Scholar
• Sisowath C, Petersen I, Veiga MI, et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis 2009;199:750-7
   PubMed Web of Science ®Google Scholar
• Malmberg M, Ngasala B, Ferreira PE, et al. Temporal trends of molecular markers associated with artemether-lumefantrine tolerance/resistance in Bagamoyo district, Tanzania. Malar J 2013;12:103
   PubMed Web of Science ®Google Scholar
• Malmberg M, Ferreira PE, Tarning J, et al. Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with pfmdr1 polymorphisms. J Infect Dis 2013;207:842-7
   PubMed Web of Science ®Google Scholar
• Kavishe RA, Paulo P, Kaaya RD, et al. Surveillance of artemether-lumefantrine associated Plasmodium falciparum multidrug resistance protein-1 gene polymorphisms in Tanzania. Malar J 2014;13:264
   PubMed Web of Science ®Google Scholar
• Baliraine FN, Rosenthal PJ. Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. J Infect Dis 2011;204:1120-4
   PubMed Web of Science ®Google Scholar
• Mbogo GW, Nankoberanyi S, Tukwasibwe S, et al. Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda. Am J Trop Med Hyg 2014;91:54-61
   PubMed Web of Science ®Google Scholar
• Conrad MD, LeClair N, Arinaitwe E, et al. Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children. J Infect Dis 2014;210:344-53
   PubMed Web of Science ®Google Scholar
• Van Schalkwyk DA, Burrow R, Henriques G, et al. Culture-adapted Plasmodium falciparum isolates from UK travellers: in vitro drug sensitivity, clonality and drug resistance markers. Malar J 2013;12:320
   PubMed Web of Science ®Google Scholar
• Dahlström S, Ferreira PE, Veiga MI, et al. Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa. J Infect Dis 2009;200:1456-64
   PubMed Web of Science ®Google Scholar
• Venkatesan M, Gadalla NB, Stepniewska K, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg 2014;91:833-43
   PubMed Web of Science ®Google Scholar
• Taylor SM, Parobek CM, DeConti DK, et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis 2015;211:680-8
   PubMed Web of Science ®Google Scholar
• Takala-Harrison S, Clark TG, Jacob CG, et al. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci U S A 2013;110:240-5
   PubMed Web of Science ®Google Scholar
• Takala-Harrison S, Jacob CG, Arze C, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis 2015;211:670-9
   PubMed Web of Science ®Google Scholar
• Tyner SD, Lon C, Se Y, et al. Ex vivo drug sensitivity profiles of Plasmodium falciparum field isolates from Cambodia and Thailand, 2005 to 2010, determined by a histidine-rich protein-2 assay. Malar J 2012;11:198
   PubMed Web of Science ®Google Scholar
• Lim P, Alker AP, Khim N, et al. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J 2009;8:11
   PubMed Web of Science ®Google Scholar
• Lim P, Dek D, Try V, et al. Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in western, northern, and eastern Cambodia, 2011-2012: association with molecular markers. Antimicrob Agents Chemother 2013;57:5277-83
   PubMed Web of Science ®Google Scholar
• Witkowski B, Khim N, Chim P, et al. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother 2013;57:914-23
   PubMed Web of Science ®Google Scholar
• Miotto O, Almagro-Garcia J, Manske M, et al. Multiple populations of artemisinin resistant Plasmodium falciparum in Cambodia. Nat Genet 2013;45:648-55
   PubMed Web of Science ®Google Scholar
• Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014;505:50-5
   PubMed Web of Science ®Google Scholar
• Amaratunga C, Witkowski B, Dek D, et al. Plasmodium falciparum founder populations in western Cambodia have reduced artemisinin sensitivity in vitro. Antimicrob Agents Chemother 2014;58:4935-7
   PubMed Web of Science ®Google Scholar
• Amaratunga C, Witkowski B, Khim N, et al. Artemisinin resistance in Plasmodium alciparum. Lancet Infect Dis 2014;14:449-50
   PubMed Web of Science ®Google Scholar
• Gosi P, Lanteri CA, Tyner SD, et al. Evaluation of parasite subpopulations and genetic diversity of the msp1, msp2 and glurp genes during and following artesunate monotherapy treatment of Plasmodium falciparum malaria in Western Cambodia. Malar J 2013;12:403
   PubMed Web of Science ®Google Scholar
• Miao M, Wang Z, Yang Z, et al. Genetic diversity and lack of artemisinin selection signature on the Plasmodium falciparum ATP6 in the Greater Mekong subregion. PLoS One 2013;8:e59192
   PubMedGoogle Scholar
• Parker D, Lerdprom R, Srisatjarak W, et al. Longitudinal in vitro surveillance of Plasmodium falciparum sensitivity to common anti-malarials in Thailand between 1994 and 2010. Malar J 2012;11:290
   PubMedGoogle Scholar
• Veiga MI, Ferreira PE, Jörnhagen L, et al. Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance. PLoS One 2011;6:e20212
   PubMed Web of Science ®Google Scholar
• Mungthin M, Khositnithikul R, Sitthichot N, et al. Association between the pfmdr1 gene and in vitro artemether and lumefantrine sensitivity in Thai isolates of Plasmodium falciparum. Am J Trop Med Hyg 2010;83:1005-9
   PubMed Web of Science ®Google Scholar
• Na-Bangchang K, Muhamad P, Ruaengweerayut R, et al. Identification of resistance of Plasmodium falciparum to artesunate-mefloquine combination in an area along the Thai-Myanmar border: integration of clinico-parasitological response, systemic drug exposure, and in vitro parasite sensitivity. Malar J 2013;12:263
   PubMed Web of Science ®Google Scholar
• Huang F, Tang L, Yang H, et al. Molecular epidemiology of drug resistance markers of Plasmodium falciparum in Yunnan Province, China. Malar J 2012;11:243
   PubMedGoogle Scholar
• Wang Z, Parker D, Meng H, et al. In vitro sensitivity of Plasmodium falciparum from China–Myanmar border area to major ACT drugs and polymorphisms in potential target genes. PLoS One 2012;7:e30927
   PubMedGoogle Scholar
• Zakeri S, Hemati S, Pirahmadi S, et al. Molecular assessment of atpase6 mutations associated with artemisinin resistance among unexposed and exposed Plasmodium falciparum clinical isolates to artemisinin-based combination therapy. Malar J 2012;11:373
   PubMedGoogle Scholar
• Gupta B, Xu S, Wang Z, et al. Plasmodium falciparum multidrug resistance protein 1 (pfmrp1) gene and its association with in vitro drug susceptibility of parasite isolates from north-east Myanmar. J Antimicrob Chemother 2014;69:2110-17
   PubMed Web of Science ®Google Scholar
• Brasil LW, Areas AL, Melo GC, et al. Pfatp6 molecular profile of Plasmodium falciparum isolates in the western Brazilian Amazon. Malar J 2012;11:111
   PubMedGoogle Scholar
• Legrand E, Yrinesi J, Ekala M-T, et al. Discordant temporal evolution of Pfcrt and Pfmdr1 genotypes and Plasmodium falciparum in vitro drug susceptibility to 4-aminoquinolines after drug policy change in French Guiana. Antimicrob Agents Chemother 2012;56:1382-9
   PubMed Web of Science ®Google Scholar
• Adhin MR, Labadie-Bracho M, Vreden SG. Status of potential PfATP6 molecular markers for artemisinin resistance in Suriname. Malar J 2012;11:322
   PubMedGoogle Scholar
• Labadie-Bracho M, Adhin MR. Increased pfmdr1 copy number in Plasmodium falciparum isolates from Suriname. Trop Med Int Health 2013;18:796-9
   PubMed Web of Science ®Google Scholar
• Cheeseman IH, Miller BA, Nair S, et al. A major genome region underlying artemisinin resistance in malaria. Science 2012;336:79-82
   PubMed Web of Science ®Google Scholar
• Hunja CW, Unger H, Ferreira PE, et al. Travellers as sentinels: assaying the worldwide distribution of polymorphisms associated with artemisinin combination therapy resistance in Plasmodium falciparum using malaria cases imported into Scotland. Int J Parasitol 2013;43:885-9
   PubMed Web of Science ®Google Scholar
• Kamau E, Campino S, Amenga-Etego L, et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-Saharan Africa. J Infect Dis 2015;211:1352-5
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO) Update on Artemisinin Resistance –WHO, 2014. Available from: www.who.int/malaria/publications/atoz/update-artemisinin-resistance-jan2014/en/ [Last accessed 30 April 2015]
   Google Scholar
• World Health Organization (WHO) Update on Artemisinin Resistance – September 2014. WHO. 2014. Available from: www.who.int/malaria/publications/atoz/update-artemisinin-resistance-sep2014/en/ [Last accessed 30 April 2015]
   Google Scholar
• Achan J, Abel Kakuru A, Ikilezi G, et al. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med 2012;367:2110-18
   PubMed Web of Science ®Google Scholar
• Mace KE, Mwandama D, Jafali J, et al. Adherence to treatment with artemether-lumefantrine for uncomplicated malaria in rural Malawi. Clin Infect Dis 2011;53:772-9
   PubMed Web of Science ®Google Scholar
• Cohen JL, Yavuz E, Morris A, et al. Do patients adhere to over-the-counter artemisinin combination therapy for malaria? Evidence from an intervention study in Uganda. Malar J 2012;11:83
   PubMed Web of Science ®Google Scholar
• Ambroise-Thomas P. The tragedy caused by fake antimalarial drugs. Mediterr J Hematol Infect Dis 2012;4:e2012027
   PubMedGoogle Scholar
• Nzila A, Okombo J, Ohuma E, Al-Thukair A. Update on the in vivo tolerance and in vitro reduced susceptibility to the antimalarial lumefantrine. J Antimicrob Chemother 2012;67:2309-15
   PubMed Web of Science ®Google Scholar
• Straimer J, Gnädig NF, Witkowski B, et al. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science 2015;347:428-31
   PubMed Web of Science ®Google Scholar
• Held J, Jeyaraj S, Kreidenweiss A. Antimalarial compounds in phase II clinical development. Expert Opin Invest Drugs 2015;24:363-82
   PubMed Web of Science ®Google Scholar
• White NJ, Pukrittayakamee S, Phyo AP, et al. Spiroindolone KAE609 for falciparum and vivax malaria. N Engl J Med 2014;37:403-10
   Google Scholar
• Wells TNC. Discovering and developing new medicines for malaria control and elimination. Infect Disord Drug Targets 2013;4:292-302
   Google Scholar
• Medicines for Malaria Venture (MMV) Interactive Research & Development Portfolio. Available from: www.mmv.org/research-development/rd-portfolio [Last accessed 28 April 2015]
   Google Scholar
• World Health Organization 2013. Global Technical Strategy for Malaria Control and Elimination 2016–2025. Malaria Policy Advisory Committee Meeting 13-15 March 2013, WHO HQ. Available from: www.who.int/malaria/mpac/global_technical_strategy_brief_mar2013.pdf [Last accessed 30 April 2015]
   Google Scholar
• World Health Organization 2013. Progress in the Development of The Global Strategic Plan for Plasmodium vivax Control and Elimination. Malaria Policy Advisory Committee Meeting, 11-13 September 2013, Crowne Plaza Hotel, Geneva. Available from: www.who.int/malaria/mpac/mpac_sep13_global_p_vivax_strategy_update.pdf [Last accessed 30 April 2015]
   Google Scholar
• World Health Organization 2012. T3 – Test. Treat. Track, Scaling up diagnostic testing, treatment and surveillance for malaria. Available from: http://www.who.int/malaria/publications/atoz/t3_brochure/en/ [Last accessed 30 April 2015]
   Google Scholar